4/A//SEC Filing
Mattila Jyrki 4/A
Accession 0001209191-09-023581
CIK 0001182129other
Filed
Apr 29, 8:00 PM ET
Accepted
Apr 30, 6:02 PM ET
Size
7.2 KB
Accession
0001209191-09-023581
Insider Transaction Report
Form 4/AAmended
Mattila Jyrki
Executive Vice President
Transactions
- Award
Nonqualified Stock Option (Right to Buy)
2009-02-27+30,000→ 30,000 totalExercise: $32.72From: 2009-12-27Exp: 2018-02-22→ Common Stock (30,000 underlying)
Footnotes (2)
- [F1]This option was granted to the reporting person on February 22, 2008 and accrued (subject to vesting) upon the satisfaction of certain performance criteria related to the Company's submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for XIAFLEX for the treatment of Dupuytren's contracture. The grant provided that if the BLA was filed on or before March 31, 2009 and the FDA granted expedited review to the BLA, the reporting person would receive 30,000 options. However, if expedited review was not granted by the FDA, the reporting person would receive 20,000 options. Therefore, upon the filing of the BLA on February 27, 2009, the reporting person became entitled to at least 20,000 options. On April 28, 2009, the FDA granted expedited review to the BLA and therefore the total options awarded to the reporting person was increased to 30,000.
- [F2]This option vests 33 1/3% on December 27, 2009 (the 10 month anniversary of the date of the BLA filing) with the balance vesting in two equal installments on each of October 27, 2010 and August 27, 2011.
Documents
Issuer
AUXILIUM PHARMACEUTICALS INC
CIK 0001182129
Entity typeother
Related Parties
1- filerCIK 0001297318
Filing Metadata
- Form type
- 4/A
- Filed
- Apr 29, 8:00 PM ET
- Accepted
- Apr 30, 6:02 PM ET
- Size
- 7.2 KB